New registry aims to unlock secrets of rare childhood diseases
NCT ID NCT05619900
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study collects information from up to 250 patients with lysosomal storage diseases (like certain forms of MPS, Pompe, Gaucher, and Wolman disease) to understand how these conditions develop and respond to treatments given before birth. Researchers will track symptoms, lab results, and organ function over time. The goal is to improve prenatal care and outcomes for affected children.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 250 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2022
- Expected to finish
-
May 2050
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Prenatal or postnatal patients diagnosed with a Lysosomal Storage Disease.
- Ages
-
Up to 64 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients aged 0-64 with a diagnosis of a lysosomal storage disease * Pregnant patients whose fetus has a diagnosis of a lysosomal storage disease Exclusion Criteria: * There are no current exclusion criteria
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mucopolysaccharidosis I are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
University of California San Francisco
RECRUITINGSan Francisco, California, 94143, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New enzyme therapy aims to reach the brain in MPS II
- Can a new enzyme therapy tame MPS II over time?
- Can a weekly infusion slow the toll of a rare genetic disease?
- Can a One-Time gene therapy change the future of MPS II?
- Gene Editing's lasting impact: a 10-Year safety watch
- Gene therapy watch: RGX-111 safety tracked in MPS i patients